Access to medicines in Turkey: Evaluation of the process of medicines brought from abroad
Open Access
- 1 October 2020
- journal article
- research article
- Published by Cambridge University Press (CUP) in International Journal of Technology Assessment in Health Care
- Vol. 36 (6), 585-591
- https://doi.org/10.1017/s0266462320000872
Abstract
Objective Turkey's health reforms started in 2003 with providing changes in regulatory, financing, and healthcare services. Access to health care and pharmaceuticals increased rapidly, and this resulted with an increase in public pharmaceutical expenditures. Our study aims to quantify and to evaluate the impact of a specific process within the Turkish system called “Medicines Brought From Abroad" (MBFA). Methods We reviewed the general reimbursement legislations of Social Security Institution (SSI), the guideline on MBFA, the SSI reimbursement list, the list of MBFA published by the Ministry of Health to describe the current supply mechanism of medicines and, in particular, the role of MBFA. Results Total costs of the of MBFA medicines over the period 2011–17 went up to more than 408 million. The highest budget impact was for eculizumab for “paroxysmal nocturnal hemoglobinuria” (PNH), covering 31 percent of total MBFA costs and 2.3 percent of overall drug costs in 2017. Conclusions Turkey faced significant challenges for creating an access pathway for innovative medicines while continuing the sustainability of the public pharmaceutical budget like many other countries. Therefore, it may be argued that Turkey needs to create an independent health technology assessment organization to provide sustainable access to medicines in the future.Keywords
This publication has 12 references indexed in Scilit:
- Economic evaluation of prescribing conventional and newer oral anticoagulants in older adultsExpert Review of Pharmacoeconomics & Outcomes Research, 2018
- Access to High Cost Medicines: An OverviewPublished by Elsevier BV ,2018
- Using health technology assessment to assess the value of new medicines: results of a systematic review and expert consultation across eight European countriesThe European Journal of Health Economics, 2017
- HOW IS CURRENT PHARMACEUTICALS PRICING POLICY ON GENERICS PERFORMING IN TURKEY REGARDING PRICE EROSIONSosyal Guvence, 2017
- Challenges for Relative Effectiveness Assessment and Early Access of Cancer Immunotherapies in EuropeFrontiers in Medicine, 2016
- The Uk Early Access To Medicines Scheme: A 2-Year Status Update On Successes, Issues And ControversiesValue in Health, 2016
- Comparison of pharmaceutical pricing and reimbursement systems in Turkey and certain EU countriesSpringerPlus, 2016
- Relative effectiveness assessments of oncology medicines for pricing and reimbursement decisions in European countriesAnnals of Oncology, 2016
- Transforming Turkey's Health System — Lessons for Universal CoverageThe New England Journal of Medicine, 2015
- Temporary Authorization for Use: Does the French Patient Access Programme for Unlicensed Medicines Impact Market Access After Formal Licensing?PharmacoEconomics, 2013